These data supported the advancement of epacadostat in clinical trials for advanced cancers, and some data have been recently published.66–68 Results highlight that epacadostat (4) is a well-tolerated compound and reduces plasma kynurenine levels in patients with a maximal inhibition of IDO1 at doses higher than 100 mg twice daily. The gene discussed is IDO1; the disease is cancer.